BMRN Stock Forecast: BioMarin Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$60
−1.60% on the day

The 28 Wall Street analysts covering BioMarin Pharmaceutical, Inc. hold a median 12-month price target of $89 — +47.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$11.9B
Ticker Nerd rank
51/ 100
Median analyst target
$89
Analysts covering
28
Revenue$989.7M+19.9% y/y
Operating income$111.0M
Net income$44.8M
Free cash flow$133.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.6%
1M
+7.1%
YTD
+1.7%
1Y
+15.2%
From 52W high
−14.0%
From 52W low
+21.7%
$50
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores BioMarin Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
51/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
98
Quality
78
Momentum
66
Growth
43
Accruals
42
Revisions
39
Issuance
20

Volatility (100): The share price has been relatively steady.

Issuance (20): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BMRN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMRN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120Jan 26Apr 26Jul 26Oct 26BMRNHigh $120Median $89Low $60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
21
Buy
7
Hold
0
Sell
$60
Low
$89
Median
$120
High

The green dot is the last close — the median target sits +47.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 9 moved it down.

DateFirmActionRatingTarget
13 Nov 2026Morgan StanleyMaintainsOverweight$119 → $103
4 Nov 2026JP MorganMaintainsOverweight$87 → $86
3 Nov 2026HC Wainwright & Co.ReiteratesNeutral$60
3 Nov 2026Morgan StanleyMaintainsOverweight$122 → $119
3 Nov 2026OppenheimerMaintainsOutperform$97 → $94
3 Nov 2026RBC CapitalMaintainsSector Perform$62 → $60
3 Nov 2026StifelMaintainsHold$70 → $66
21 Oct 2026Morgan StanleyMaintainsOverweight$124 → $122
20 Oct 2026Cantor FitzgeraldReiteratesOverweight$86
20 Oct 2026JP MorganMaintainsOverweight$86 → $87
15 Oct 2026UBSAssumesBuy$114 → $88
14 Oct 2026BarclaysMaintainsOverweight$111 → $114
10 Sept 2026HC Wainwright & Co.ReiteratesNeutral$60
1 Sept 2026Piper SandlerMaintainsOverweight$88 → $90
31 Aug 2026HC Wainwright & Co.MaintainsNeutral$59 → $60
31 Aug 2026JefferiesMaintainsBuy$104 → $105
19 Aug 2026BMO CapitalInitiatesOutperform$98
18 Aug 2026HC Wainwright & Co.MaintainsNeutral$60 → $59
17 Aug 2026BarclaysMaintainsOverweight$105 → $111
17 Aug 2026Piper SandlerMaintainsOverweight$82 → $88

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BMRN.

Market Radar

This page is one stock. Monday covers all of them.

BMRN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BMRN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, BioMarin Pharmaceutical, Inc. returned +15.2% against +6.9% for the S&P 500, dividends included.

BMRN vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140Jan 26Apr 26Jul 26Oct 26BMRNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMRN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−39.8%
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.3×

Cheaper than 33% of US stocks

Price / book
1.9×

Cheaper than 45% of US stocks

EV / EBITDA
18.0×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
79.5%

Higher than 90% of US stocks

Operating margin
16.3%

Higher than 74% of US stocks

Net margin
−0.5%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.3%

Higher than 44% of US stocks

Return on assets
3.9%

Higher than 70% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioMarin Pharmaceutical, Inc. has a market value of $11.9B and an enterprise value of $15.4B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 19.9% year on year.

  • Net income over the same four quarters: $73.0M, a 2.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.37.

  • Free cash flow in the twelve months to 30 June 2026: $725.1M.

  • Shares outstanding: 193.5M.

  • forward P/E: 9.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioMarin Pharmaceutical, Inc. employs 3,221 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BMRN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BMRNBioMarin Pharmaceutical, Inc.$11.9B51
TECHBio-Techne Corp.$11.3B96
HALOHalozyme Therapeutics, Inc.$10.4B96
TGTXTG Therapeutics, Inc.$10.1B78
KYMRKymera Therapeutics, Inc.$9.6B65
JAZZJazz Pharmaceuticals Plc$14.4B95
BBIOBridgeBio Pharma, Inc.$14.7B80

Take a look at BMRN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own BioMarin Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BMRN

What is the BMRN stock price forecast for 2026-2027?

The 28 Wall Street analysts covering BioMarin Pharmaceutical, Inc. have a median 12-month price target of $89, with estimates ranging from $60 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMRN stock a buy right now?

Of the 28 analysts covering BioMarin Pharmaceutical, Inc., 21 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioMarin Pharmaceutical, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMRN?

As at 21 Nov 2026, BioMarin Pharmaceutical, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will BMRN stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +47.3% from the last close, and Ticker Nerd's factor model ranks BioMarin Pharmaceutical, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMRN stock forecast for 2030?

No analyst covering BioMarin Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $120 over the next 12 months.

How has BMRN stock performed over the past year?

BioMarin Pharmaceutical, Inc. returned +15.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioMarin Pharmaceutical, Inc. do?

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions.

Company

About BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.

CEO Mr. Alexander Hardy · 3,221 employees · United States · https://www.biomarin.com